2022 Best Tech Startups in Champaign
SimBioSys is one of the 2022 best tech startups in Champaign! "The Tech Tribune staff has compiled the very best tech startups in Champaign, Illinois. In doing our research, we considered several factors including but not limited to: Revenue potential Leadership team...
SimBioSys to Showcase Latest Research on TumorScope at ASCO 2022
CHICAGO – JUNE 3, 2022 -- SimBioSys, the technology company that predicts tumor responses to therapy, announced today it will showcase research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 taking place in Chicago from June 3-7. SimBioSys...
SimBioSys Presents 9 Applications of TumorScope Platform at AACR 2022
The company’s first appearance at this prestigious cancer research conference profiles use cases of platform for cancer treatment planning and as a cancer research tool.
Biopharma Dealmakers: Virtualizing cancer to eliminate uncertainty and individualize care
No two tumors are alike. What if we could model treatment planning for each individual patient? Meet TumorScope – the first of its kind 4D Tumor Modeling platform that combines state of the art biophysical modeling, spatial profiling, and artificial intelligence to...
Novel Device May Predict Response to Therapy in Patients With Early Breast Cancer
Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology. Even with...
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care
Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data
Transforming Cancer Care with Dr. John Cole
John Cole, Co-Founder & Chief Scientific Officer of Research Park startup SimBioSys, joins the podcast! He discusses the breakthroughs his team has created for "transforming decision making and patient experience in cancer care” through a powerful software...
Wired in: Interview with Tushar Pandey
Each week, staff writer Paul Wood interviews a high-tech difference-maker. This week, meet TUSHAR PANDEY, chief executive officer at SimBioSys Inc. in the University of Illinois Research Park. The company is working on technology to allow doctors and scientists to...
Harnessing the immune system to develop breakthrough cancer therapies
The last decade in cancer care has been defined by the rapid emergence (and in some cases, dominance), of monoclonal antibody therapies, where they serve as a critical foundation of oncologic care.
Takeaways from ESMO 2022
Our chief medical officer, Dr. Anuja Antony, represented SimBioSys at the ESMO 2022 conference last month. Among the many exciting advances and developments in the breast cancer field, two topics took center stage: 1) antibody-drug conjugates (ADCs) and 2) human epidermal growth factor 2 (HER2)-low cancer.
Enabling personalized cancer care through AI and computer simulations with NVIDIA
SimBioSys® is developing the TumorScope® platform to capture what is truly unique about each patient. The NVIDIA GPU-powered platform takes a holistic and multiscale approach to assess tumor response to therapy. Pulling together all the information that’s painstakingly acquired during the diagnosis — demographic, clinical, radiological and pathological — TumorScope creates a 3D “digital twin” that virtualizes a patient’s cancer.
Huge ASCO Breakthroughs: But will these Innovations Advance Equitable Cancer Care?
Our team was present at the American Society of Clinical Oncology (ASCO) annual meeting that took place from June 3 – 7, 2022.
Perhaps the most impactful moment for breast cancer oncologists and researchers at the conference took place during the plenary session when Dr. Shanu Modi presented the results of the DESTINY-Breast04 trial.
Highlights from ESMO Breast Cancer 2022
The ESMO Breast Cancer 2022 took place in Berlin on May 3 – 5. A well-attended conference covering a broad range of breast cancer topics. Our team was there to present three posters.
Here are our takeaway messages from the conference.
Highlights from AACR2022
After two consecutive years of virtually holding the annual meeting of the American Association for Cancer Research (AACR), the conference returned to an in-person format, while retaining a hybrid option for those who prefer to join virtually.
Key take home messages from the San Antonio Breast Cancer Symposium 2021
From December 7th -10th the San Antonio Breast Cancer Symposium gathered breast cancer experts from all over the world to share the latest medical and scientific advances in the breast cancer field.
Our team attended the meeting to present our research on breast cancer. Here are some of the key take home messages from the conference.
Why is it important to raise breast cancer awareness?
Precision medicine has come a long way in terms of breast cancer treatment but more needs to be done for the non-responder patients, for those who need financial support, for minorities. Precision cancer care needs to be available for all.
Why Cancer? Why Us? Why Now?
Most of us have experienced the pain of a friend or family member’s cancer diagnosis and treatment in our lives. The process of diagnosis, treatment and monitoring — and the resulting uncertainty — has a debilitating impact. At SimBioSys, we are blessed to be able to go into work to address this problem – both incredibly personal and could have such a significant impact on humanity.
Validation of prognostic platform to further refine identification High Risk Patients indicated for Chemotherapy Free Treatment in Early-Stage Breast Cancer
We used a novel 2-paramenter pharmacokinetic modeling framework that allows biosignatures to be extracted from dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) studies that contain 3-6 timepoints spaced 60-90 seconds apart. These parameters, referred to as P1 and P2, represent leakiness from vessels into the extravascular space and vice versa.
Development of a Novel Imaging Biomarker to Ascertain Responsiveness to Immunotherapy
Currently, a lack of tests to differentiate patients likely to respond to IO vs. poor responders precludes a tailored approach to immunotherapy. Here we describe an imaging biomarker that allows physicians to target breast cancer patients with the highest likelihood of response to immunotherapies.
A 3D Visualization and Prediction Device for Breast Cancer Surgeons and their Patients
Despite chemotherapeutic advances, surgery remains a putative treatment modality for breast cancer. The type of surgery chosen, and its ultimate clinical and cosmetic consequences, depends on a surgeon’s ability to accurately assess a tumor’s size, distribution, and position in the breast relative to anatomical landmarks.
A 3D Visualization Method for Breast Cancer Surgeons and Patients
In order to accurately evaluate the potential success of various surgical options, a surgeon must mentally translate these 2D images into more realistic, 3D image to visualize breast and tumor morphologies.
Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial
We developed the TumorScope engine, a software platform that utilizes pretreatment diagnostic data to build a computational tumor model that simulates in vivo tumor characteristics and interactions, incorporating morphology, metabolism, vascularity, and nutrient and drug delivery.
pCR Score: A Novel Prognostic Method to Estimate the Predictive Probability of pCR in Early-Stage Breast Cancer Patients.
To drive further utility, we now investigate a pCR score as a continuous outcome (0-100) to establish a prognostic system that evaluates the predictive probability that a patient will achieve pCR with any SOC NAT regimen.
T-cell metabolic activity is impacted by the nutrient composition within the tumor microenvironment
Our results demonstrated that the local nutrient composition has a dramatic impact on T cell functionality, with fundamental cellular behaviors being significantly impaired by a reduction in key nutrients such as glucose and oxygen.
The Next Generation of Immunotherapy Response Signatures Revealed by Biophysical Simulations
Here, we present a proof-of-concept approach for the rapid, non-invasive assessment of immunotherapy response prediction using biomarker imaging signatures.
Biophysical simulation approach for dose escalation in Phase I clinical trials
Here we performed a proof-of-concept study using trastuzumab emtansine (TDM1), a targeted drug for HER2-enriched breast cancer, to demonstrate how biophysical modeling can support dose selection in phase I clinical trials.
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform
Purpose Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) is largely dependent on breast cancer subtype, but no clinical-grade model exists to predict response and guide selection of treatment. A biophysical simulation...
Precision Medicine in Breast Cancer
Thank you for your interest in our white paper. Please fill out the form below to be directed to a downloadable version